INDEPENDENT IPO / PLACEMENT / LOCKUP RESEARCH - US & APAC
The ECM Research
you won’t get from the banks
Aequitas delivers independent analysis of US & APAC IPOs, placements and lock-up expiries for institutional investors.
Fundamental, bottom-up research
Proprietary quantitative framework overlay
Consistent analysis; every deal, every stage
We cover US and APAC deals over US$100m (ex-Biotech) from pre-IPO through to listing
US IPOs
US$100m+
APAC IPOs
US$100m+
APAC Placements US$100m+
APAC
Lock-up
expiries
Ex Bio-tech. APAC includes Hong Kong, China ADRs, India, ASEAN, South Korea, Japan, Australia, New Zealand, and Asia-linked cross-border listings (ie Taiwan GDRs)
We recommend ‘avoid’ on ~60% of IPOs we cover,
with 73% accuracy
1,058
IPOs covered since 2015
73.2% accuracy · 40.5% participation
1,645
Placements since 2015
69.5% accuracy · 75.5% participation